Eiger BioPharmaceuticals Appoints Market Access, Public Policy Expert, and Biotech Veteran Amit K. Sachdev to Board of Directors
"Mr. Sachdev has an extensive track record of success in leadership posts across the business at Vertex over the last decade," said
"I am very pleased to join Eiger's Board at this exciting point in the Company's evolution and look forward to working closely with the other Board members in supporting Eiger's management team to advance multiple, first-in-class, rare and ultra-rare disease programs to patients with unmet medical needs," said Mr. Sachdev.
Prior to joining Vertex, Mr. Sachdev served as Executive Vice President at the
Eiger is a late-stage biopharmaceutical company focused on the accelerated development and commercialization of a pipeline of targeted, first-in-class therapies for rare and ultra-rare diseases. The Company's lead program, lonafarnib, a first-in-class prenylation inhibitor for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3. The Company is also preparing an NDA and MAA, with plans to file in 2019, for lonafarnib in the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies. For additional information about Eiger, please visit www.eigerbio.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-appoints-market-access-public-policy-expert-and-biotech-veteran-amit-k-sachdev-to-board-of-directors-300831855.html